Vaxcyte, Inc.
PCVXHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Vaxcyte, Inc. (PCVX) is listed under Biotechnology. The company carries a $8.12B market cap, placing it firmly in the mid-cap category. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Market Cap
$8.12B
Beta
1.22
P/E (TTM)
—
P/E (Fwd)
-7.57
EPS (TTM)
$-6.89
EPS (Fwd)
$-7.42
ROE
-30.6%
ROA
-20.2%
Cash
$1.74B
Total Debt
$116.3M
Free CF
-$439.8M
52W Change
55.2%
Annual Financials
Cash vs Debt
With $1.74B in cash and $116.3M in debt, PCVX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$439.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -30.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, PCVX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Vaxcyte, Inc. and its sector.